Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients

Marten Werner, Sven Almer, Hanne Prytz, Stefan Lindgren, Sven Wallerstedt, Einar Bjoersson, Annika Bergquist, Hanna Sandberg-Gertzen, Rolf Hultcrantz, Per Sangfelt, Ola Weiland, Ake Danielsson

Research output: Contribution to journalArticlepeer-review


Background/Aims: Autoimmune Hepatitis (AIH) is a liver disease which may lead to liver cirrhosis. Cirrhosis is a well-known risk factor for hepatocellular cancer. Lymphoma is a disease, where immune modulating drugs as well as the autoimmune disease itself may contribute to the elevated risk. The aim was to investigate the risks of malignancies in a large cohort of AIH patients. Methods: Four hundred and seventy-three patients with AIH were matched to the Swedish national cancer register as well as to the death cause register. Results: We found an overall higher risk of malignancies in the cohort of A I H patients from the date of diagnosis with a SIR of 1.51 (95% CI 1.10-2.03). SIR in the subpopulation of well defined catchment areas and complete case finding was 23.28 (95% CI 7.5-54.34) for HCC. Lymphomas were found a SIR of 13.09 (95% CI 4.22-30.56). Conclusions: There was an overall increased risk of malignancies in a cohort of AIH patients, which manly was caused by hepatobiliary cancers. However, the true risk of HCC in an AIH cirrhotic cohort has yet to be investigated. A significantly higher risk of lymphomas was also found, but no clear cut association to the use of immune modulators. (C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)388-393
JournalJournal of Hepatology
Issue number2
Publication statusPublished - 2009

Subject classification (UKÄ)

  • Gastroenterology and Hepatology

Free keywords

  • Malignancies
  • Lymphoma
  • Autoimmune hepatitis
  • Hepatocellular carcinoma


Dive into the research topics of 'Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients'. Together they form a unique fingerprint.

Cite this